BCEL · Atreca, Inc. - Financials
Annual line items from SEC XBRL filings, sourced from EDGAR's Company Facts API with fallback to the quarterly Financial Statement Data Sets. See issuer overview for Form 4 activity and 10-K signals.
Income Statement
| Line item | FY 2022 | FY 2021 | FY 2020 | FY 2019 |
|---|---|---|---|---|
| Revenue | - | - | - | - |
| Cost of Revenue | - | - | - | - |
| Gross Profit | - | - | - | - |
| R&D | $66.83M | $78.35M | $62.05M | $32.51M |
| SG&A | $31.47M | $31.95M | $26.83M | $7.06M |
| Total Operating Expenses | $98.74M | $110.30M | $88.88M | $39.57M |
| D&A | $5.46M | $4.55M | $2.38M | $1.41M |
| Operating Income | ($97.16M) | ($109.33M) | ($86.33M) | ($37.94M) |
| Interest Expense | - | $3.0K | $4.0K | $9.0K |
| Income Tax | - | $1.0K | $1.0K | ($1.0K) |
| Net Income | ($97.16M) | ($109.33M) | ($86.33M) | ($37.94M) |
| EPS - Basic | ($2.52) | ($2.70) | - | - |
| EPS - Diluted | ($2.52) | ($2.70) | - | - |
Balance Sheet
| Line item | FY 2022 | FY 2021 | FY 2020 | FY 2019 |
|---|---|---|---|---|
| Cash & Equivalents | $30.82M | $94.75M | $60.79M | $157.95M |
| Accounts Receivable | - | - | - | - |
| Inventory | - | - | - | - |
| Accounts Payable | $1.74M | $3.35M | $5.22M | $2.13M |
| Current Assets | $78.03M | $122.37M | $249.12M | $176.12M |
| Total Assets | $155.03M | $200.06M | $272.06M | $195.72M |
| Current Liabilities | $16.29M | $16.90M | $17.42M | $7.95M |
| Long-term Debt | - | - | - | - |
| Total Liabilities | $76.62M | $45.13M | $30.01M | $8.76M |
| Stockholders' Equity | $78.41M | $154.93M | $242.06M | $186.95M |
| Retained Earnings | ($456.92M) | ($359.77M) | ($250.44M) | ($164.11M) |
Cash Flow
| Line item | FY 2022 | FY 2021 | FY 2020 | FY 2019 |
|---|---|---|---|---|
| Operating Cash Flow | ($80.72M) | ($60.92M) | ($66.67M) | ($34.70M) |
| Investing Cash Flow | $12.55M | $89.24M | ($159.00M) | $20.66M |
| Financing Cash Flow | $3.90M | $5.45M | $128.87M | $120.30M |
| CapEx | $885.0K | $35.09M | $5.03M | $1.76M |
| Free Cash Flow | ($81.61M) | ($96.01M) | ($71.70M) | ($36.46M) |
Ratios
| Metric | FY 2022 | FY 2021 | FY 2020 | FY 2019 |
|---|---|---|---|---|
| Profitability | ||||
| Gross margin | - | - | - | - |
| Operating margin | - | - | - | - |
| EBITDA margin | - | - | - | - |
| Net margin | - | - | - | - |
| Free cash flow margin | - | - | - | - |
| FCF / Net income | 0.84 | 0.88 | 0.83 | 0.96 |
| R&D / Revenue | - | - | - | - |
| SG&A / Revenue | - | - | - | - |
| Effective tax rate | - | - | - | - |
| Return on assets | -62.7% | -54.6% | -31.7% | -19.4% |
| Return on equity | -123.9% | -70.6% | -35.7% | -20.3% |
| Return on invested capital | - | - | - | - |
| Liquidity | ||||
| Current ratio | 4.79 | 7.24 | 14.30 | 22.16 |
| Quick ratio | 4.79 | 7.24 | 14.30 | 22.16 |
| Cash ratio | 1.89 | 5.61 | 3.49 | 19.88 |
| Leverage | ||||
| Debt / Equity | - | - | - | - |
| Debt / Assets | - | - | - | - |
| Debt / EBITDA | - | - | - | - |
| Interest coverage | - | -36441.7x | -21583.5x | -4215.7x |
| Equity multiplier | 1.98 | 1.29 | 1.12 | 1.05 |
| Liabilities / Assets | 0.49 | 0.23 | 0.11 | 0.04 |
| Efficiency | ||||
| Asset turnover | - | - | - | - |
| Inventory turnover | - | - | - | - |
| Days sales outstanding | - | - | - | - |
| Days inventory outstanding | - | - | - | - |
| Days payable outstanding | - | - | - | - |
| Cash conversion cycle | - | - | - | - |
| Valuation | ||||
| P / E | - | - | - | - |
| P / B | - | - | - | - |
| P / S | - | - | - | - |
| EV / EBITDA | - | - | - | - |
| Growth | ||||
| Revenue growth (YoY) | - | - | - | - |
| Revenue CAGR (3y) | - | - | - | - |
| Revenue CAGR (5y) | - | - | - | - |
| Gross profit growth (YoY) | - | - | - | - |
| Operating income growth (YoY) | 11.1% | -26.6% | -127.5% | - |
| Net income growth (YoY) | 11.1% | -26.6% | -127.6% | - |
| EPS growth (YoY) | 6.7% | - | - | - |
| EPS CAGR (3y) | - | - | - | - |
| EPS CAGR (5y) | - | - | - | - |
| FCF growth (YoY) | 15.0% | -33.9% | -96.6% | - |
| FCF CAGR (5y) | - | - | - | - |
| Book value growth (YoY) | -49.4% | -36.0% | 29.5% | - |
Stability scores
Piotroski F-score
FY 2022 · 9-point quality
1/9
Weak
- ✗Net income positive
- ✗Operating cash flow positive
- ✗ROA improved YoY
- ✓Cash flow > net income
- -Long-term debt decreased
- ✗Current ratio improved
- ✗No share dilution
- -Gross margin improved
- -Asset turnover improved
Peer comparison
Same SIC group: Pharmaceutical Preparations
Comparing Atreca against the 5 most active filers in the same SIC group.